Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

New FDA-Approved HeartLight X3 System for Cardiac Ablations Is Available at Delray Medical Center: First in Palm Beach County, Florida

Delray Medical Center, part of the Palm Beach Health Network, is the first hospital in Palm Beach County to offer patients The HeartLight X3 System for cardiac ablations.  This procedure offers some of the most advanced treatments for patients with atrial fibrillation, the most common heart rhythm disorder.  Interventional cardiologist Dr. Mark Freher is the first surgeon to perform the procedure in our area using the system’s miniaturized camera and advanced laser technology.

“At Delray Medical Center, we are committed to innovation and offering patients early access to many of the latest cardiac treatment advancements, including devices like the HeartLight X3 System,” said Dr. Mark Freher, electrophysiologist on staff at Delray Medical Center. “We have taken the necessary steps to perform surgical procedures in a safe and secure environment, and our community can rest assured that we have the appropriate supplies and protocols in place.”

The HeartLight X3 Endoscopic Ablation System, developed by CardioFocus Inc.,  is designed for physicians to perform pulmonary vein isolation (PVI) procedures with accuracy, precision, and confidence. The PVI procedure creates areas of scar tissue around the pulmonary veins to block the electrical signals that cause arrhythmia. While older treatments rely on x-ray or mapping support for guidance, the X3 System’s innovative HeartLight catheter is equipped with a miniature video camera and “headlight” to deliver a direct, live-action view of the inside of the heart. The system also enables the physician to customize the amount of laser energy used during the procedure based upon the patient’s specific needs, and HeartLight’s unique balloon design adapts to the heart’s specific anatomy.

“I want to congratulate Dr. Freher and our cardiac team on becoming the first in Palm Beach County to perform this advanced procedure,” said Maggie Gill, chief executive officer of the Palm Beach Health Network and Delray Medical Center.  It is very rewarding to be able to continue to bring some of the latest medical innovations to our area, and we remain on the forefront of the latest cardiac treatment options.”

AFib is a serious condition that causes a quick, often chaotic heartbeat. Left untreated it can lead to weakness, breathlessness, fainting and a decreased quality of life. In addition, AFib patients face an increased risk of stroke, which is the fifth leading cause of death in the state of Florida. With proper treatment, patients affected by this debilitating condition can get safe symptom relief.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy